Sai Parenterals IPO has received a muted response from investors, with subscription levels remaining very low even after the initial days of bidding. The issue saw only about 4% subscription, indicating cautious sentiment in the market.
The lack of strong interest is also reflected in the grey market, where no premium is being seen currently. This suggests that investors are uncertain about listing gains and overall valuation.
Market experts believe that ongoing volatility and selective investing behaviour are affecting IPO participation. However, final subscription numbers may improve closer to closing as institutional investors step in.
